Related Experiment Video

Updated: Aug 20, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Sensitization of chemotherapy by anti-HER

Akemi Kataoka1, Mayumi Ishida, Shigeru Murakami

  • 1Department of Breast Oncology, National Hospital Kyushu Cancer Center, Notame 3-1-1, Minami-ku, Fukuoka 811-1395, Japan.

Breast Cancer (Tokyo, Japan)
|November 20, 2004
PubMed

Insights

Trastuzumab, an antibody targeting human epidermal growth factor receptor-2 (HER2), improves outcomes in HER2-overexpressing metastatic breast cancer. Combination therapies show efficacy but require careful monitoring for cardiotoxicity.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Human epidermal growth factor receptor-2 (HER2) overexpression is a key driver in a subset of breast cancers.
  • Targeting HER2 has become a cornerstone of treatment for HER2-positive breast cancer.
  • Trastuzumab, a monoclonal antibody, is a primary therapeutic agent in this context.

Purpose of the Study:

  • To review current therapeutic strategies targeting HER2 in breast cancer.
  • To present findings from clinical studies involving trastuzumab and other HER2-targeting agents.
  • To summarize data on trastuzumab-based combination chemotherapies and novel HER2-targeted drugs.

Main Methods:

  • Review of clinical studies and preclinical models evaluating trastuzumab efficacy.
  • Analysis of combination therapies involving trastuzumab with various chemotherapeutic agents.
  • Examination of novel drugs targeting HER2 and associated signal transduction pathways.

Main Results:

  • Trastuzumab demonstrates activity in HER2-overexpressing metastatic breast cancer, as a single agent or in combination with chemotherapy.
  • Preclinical studies indicate additive and synergistic anti-tumor effects of trastuzumab with chemotherapeutic agents.
  • A Phase III trial confirmed improved response rates and survival with trastuzumab plus chemotherapy.
  • Cardiotoxicity concerns with anthracyclines led to studies combining trastuzumab with taxanes, vinorelbine, and platinum salts.

Conclusions:

  • Trastuzumab-based therapies are effective in HER2-positive metastatic breast cancer.
  • Combination regimens offer improved outcomes but necessitate careful management of side effects, particularly cardiotoxicity.
  • Ongoing research focuses on novel HER2-targeting agents and combination strategies to enhance efficacy and safety.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...